In conclusion, we demonstrate that the m6A writer METTL3 induces m6A-SCAP-cholesterol axis to suppress the activation of antitumor CD8+ T cells, thereby promoting NAFLD-HCC. This evidence concerns the gene METTL3 and metabolic dysfunction-associated steatotic liver disease.